Diisopropylfluorophosphate-P32 (DFP-P32) as a Label for Granulocytes

  • Spencer O. Raab


Diisopropylfluorophosphate (DFP), a potent and irreversible esterate inhibitor, was first suggested as a red cell label by Grob, Lilienthal, Harvey, and Jones in 1947 [1]. In 1954 Cohen and Warringa [2] described the use of DFP containing radioactive phosphorous (DFP-P32) as a label for erythrocytes, and two years later Leeksma and Cohen [3] described the use of DFP-P32 as a platelet label. The latter authors found relatively little label in leukocytes.


Isotonic Saline Granulocyte Count Cell Button Blood Granulocyte Absolute Granulocyte Count 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Grob, D., Lilienthal. J. L., Jr., Harvey, A.M., and Jones, B. F., Bull. Johns Hopkins Hosp. 81:217 (1947).Google Scholar
  2. 2.
    Cohen, J.A., and Warringa, M.G. P. J., J. Clin. Invest, 33: 459 (1954).CrossRefGoogle Scholar
  3. 3.
    Leeksma, C. H. W., and Cohen, J.A., J. Clin. Invest. 35: 964 (1956).CrossRefGoogle Scholar
  4. 4.
    Athens, J. W., Mauer, A. M., Ashenbrucker, H., Cartwright, G. E., and Wintrobe, M. M., Blood 14: 303 (1959).Google Scholar
  5. 5.
    Mauer, A. M., Athens, J. W., Ashenbrucker, H., Cartwright, G. E., and Wintrobe, M. M., J. Clin. Invest. 39: 1481 (1960).CrossRefGoogle Scholar
  6. 6.
    Kurth, D., Athens, J. W., Cronkite, E. P., Cartwright, G. E., and Wintrobe, M. M., Proc. Soc. Exp. Biol. Med. 107: 422 (1961).Google Scholar
  7. 7.
    Athens, J. W., Raab, S. O., Haab, O. P., Mauer, A.M., Ashenbrucker, H., Cartwright, G. E., and Wintrobe, M. M., J. Clin. Invest. 40: 159 (1961).CrossRefGoogle Scholar
  8. 8.
    Vejlens, G., Acta Pathol. Microbiol. Scand. Suppl. 33 (1938).Google Scholar
  9. 9.
    Athens, J. W., Haab, O. P., Raab, S. O., Mauer, A. M., Ashenbrucker, H., Cartwright, G.E., and Wintrobe, M.M., J. Clin. Invest. 40: 989 (1961).CrossRefGoogle Scholar
  10. 10.
    Oosterbaan, R. A., Jausz, H. S., and Cohen, J.A., Biochem. Biophys. Acta 20: 402 (1956).CrossRefGoogle Scholar
  11. 11.
    Schaffer, N. K., Simet, L., Harshman, S., Engle, R. R., and Drisko, R. W., J. Biol. Chem. 225: 197 (1957).Google Scholar
  12. 12.
    Mazur, A., and Bodansky, O., J. Biol. Chem. 163: 261 (1946).Google Scholar
  13. 13.
    Jandorf, B. J., and McNamara, P.D., J. Pharmacol. Exp. Therap. 98: 77 (1950).Google Scholar
  14. 14.
    Eadie, G. S., Smith, W. W., and Brown, I. W., Jr., J. Gen. Physiol. 43: 825 (1960).CrossRefGoogle Scholar
  15. 15.
    Hjort, P. F., Paputchis, H., and Cheney, B., J. Lab. Clin. Med. 55: 416 (1960).Google Scholar
  16. 16.
    Mayer, K., and Ley, A. B., Clin. Res. Proc. 4: 80 (1956).Google Scholar
  17. 17.
    Bove, J.R., and Ebaugh, F.G., Jr., J. Lab. Clin. Med. 51: 916 (1958).Google Scholar
  18. 18.
    Pollycove, M., Dal Santo, G., and Lawrence, J. H., Clin. Res. Proc. 6: 45 (1958).Google Scholar
  19. 19.
    Eernisse, J.G., and van Rood, J. J., Brit. J. Haematol. 7: 382 (1961).CrossRefGoogle Scholar

Copyright information

© New England Nuclear Corporation 1965

Authors and Affiliations

  • Spencer O. Raab
    • 1
  1. 1.Department of MedicineUniversity of Utah College of MedicineSalt Lake CityUSA

Personalised recommendations